487,728 Shares in Fate Therapeutics, Inc. $FATE Acquired by Ieq Capital LLC

Ieq Capital LLC bought a new stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 487,728 shares of the biopharmaceutical company’s stock, valued at approximately $1,317,000.

A number of other large investors have also made changes to their positions in the stock. Commonwealth Equity Services LLC acquired a new stake in Fate Therapeutics during the 4th quarter worth $26,000. Bridgeway Capital Management LLC bought a new position in Fate Therapeutics in the second quarter valued at approximately $28,000. Callan Family Office LLC acquired a new position in Fate Therapeutics in the 2nd quarter worth $29,000. Corient Private Wealth LLC bought a new position in shares of Fate Therapeutics during the fourth quarter worth about $29,000. Finally, Bank of New York Mellon Corp bought a new stake in shares of Fate Therapeutics in the second quarter worth $31,000. Institutional investors and hedge funds own 97.54% of the company’s stock.

Fate Therapeutics Price Performance

FATE opened at $2.57 on Thursday. Fate Therapeutics, Inc. has a 1 year low of $0.93 and a 1 year high of $3.23. The firm’s fifty day moving average price is $2.60 and its two-hundred day moving average price is $1.94. The company has a market capitalization of $307.94 million, a price-to-earnings ratio of -2.45 and a beta of 2.52.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). The company had revenue of $2.08 million during the quarter, compared to analysts’ expectations of $1.94 million. Fate Therapeutics had a negative return on equity of 65.08% and a negative net margin of 1,941.09%. As a group, equities analysts anticipate that Fate Therapeutics, Inc. will post -1.06 EPS for the current year.

Wall Street Analysts Forecast Growth

FATE has been the subject of a number of recent analyst reports. Wells Fargo & Company increased their price target on shares of Fate Therapeutics from $2.50 to $3.50 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Piper Sandler reaffirmed an “overweight” rating and set a $8.00 target price (up from $6.00) on shares of Fate Therapeutics in a report on Friday, August 14th. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Fate Therapeutics in a research report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Fate Therapeutics in a research report on Friday, August 7th. Finally, Jefferies Financial Group set a $4.00 price target on shares of Fate Therapeutics in a report on Tuesday, May 19th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Fate Therapeutics currently has an average rating of “Hold” and a consensus price target of $5.90.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of first?in?class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off?the?shelf natural killer (NK) and T?cell products designed to overcome limitations of donor?derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC?derived cell therapy candidates in active clinical development.